Karyopharm Therapeutics Inc (KPTI)
0.814
-0.02
(-2.78%)
USD |
NASDAQ |
Nov 15, 16:00
0.82
+0.01
(+0.74%)
Pre-Market: 08:31
Karyopharm Therapeutics Revenue (Quarterly): 38.78M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 38.78M |
| June 30, 2024 | 42.79M |
| March 31, 2024 | 33.13M |
| December 31, 2023 | 33.75M |
| September 30, 2023 | 36.01M |
| June 30, 2023 | 37.58M |
| March 31, 2023 | 38.70M |
| December 31, 2022 | 33.58M |
| September 30, 2022 | 36.14M |
| June 30, 2022 | 39.68M |
| March 31, 2022 | 47.67M |
| December 31, 2021 | 126.27M |
| September 30, 2021 | 37.69M |
| June 30, 2021 | 22.60M |
| March 31, 2021 | 23.26M |
| December 31, 2020 | 35.10M |
| September 30, 2020 | 21.33M |
| June 30, 2020 | 33.51M |
| March 31, 2020 | 18.14M |
| December 31, 2019 | 18.10M |
| September 30, 2019 | 13.15M |
| June 30, 2019 | 9.493M |
| March 31, 2019 | 0.155M |
| December 31, 2018 | 0.206M |
| September 30, 2018 | 0.239M |
| Date | Value |
|---|---|
| June 30, 2018 | 19.89M |
| March 31, 2018 | 10.00M |
| December 31, 2017 | 1.534M |
| September 30, 2017 | |
| June 30, 2017 | 0.003M |
| March 31, 2017 | 0.068M |
| December 31, 2016 | 0.047M |
| September 30, 2016 | 0.048M |
| June 30, 2016 | 0.059M |
| March 31, 2016 | |
| December 31, 2015 | 0.025M |
| September 30, 2015 | 0.075M |
| June 30, 2015 | 0.15M |
| March 31, 2015 | |
| December 31, 2014 | 0.015M |
| September 30, 2014 | 0.021M |
| June 30, 2014 | 0.021M |
| March 31, 2014 | 0.171M |
| December 31, 2013 | 0.021M |
| September 30, 2013 | |
| June 30, 2013 | 0.133M |
| March 31, 2013 | 0.233M |
| December 31, 2012 | 0.033M |
| September 30, 2012 | 0.034M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
18.10M
Minimum
Dec 2019
126.27M
Maximum
Dec 2021
37.69M
Average
35.55M
Median
Revenue (Quarterly) Benchmarks
| Bruker Corp | 864.40M |
| Ionis Pharmaceuticals Inc | 133.81M |
| Apellis Pharmaceuticals Inc | 196.83M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | 0.35M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.07M |
| Total Expenses (Quarterly) | 65.07M |
| EPS Diluted (Quarterly) | -0.26 |
| Enterprise Value | 159.07M |
| Gross Profit Margin (Quarterly) | 96.65% |
| Profit Margin (Quarterly) | -82.70% |
| Earnings Yield | -140.0% |
| Normalized Earnings Yield | -175.51 |